Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Overview of attention for article published in eClinicalMedicine, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 4 news outlets
policy: 2 policy sources
twitter: 60 X users

patent: 1 patent
reddit: 1 Redditor

Readers on

mendeley: 198 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Potential benefits and limitations of mRNA technology for vaccine research and development for infectious diseases and virus-induced cancers: report of the WHO Science Council

Cited by World Health Organization (WHO) on 13 Dec 2023

The World Health Organization (WHO) is the directing and coordinating authority for health within the United Nations system.

A study assessing scientific, engineering, legal and economic considerations of flexible EU manufacturing and innovation of medical countermeasures for serious cross-border threats to health

Cited by The Publications Office of the European Union on 15 Jun 2023

The Publications Office of the European Union (Publications Office), based in Luxembourg, is an interinstitutional office whose task is to publish the publications of the institutions of the European Union.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.